PNC Financial Services Group’s Zevra Therapeutics ZVRA Stock Holding History

PNC Financial Services Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.85K	Buy	338 +56	+20%	+$623	﹤0.01%	4402
2026 Q1	$2.63K	Buy	282 +188	+200%	+$1.7K	﹤0.01%	4501
2025 Q4	$842	Sell	94 -1,223	-93%	-$11.6K	﹤0.01%	4736
2025 Q3	$12.5K	Buy	1,317 +6	+0.5%	+$60	﹤0.01%	3846
2025 Q2	$11.6K	Sell	1,311 -195	-13%	-$1.58K	﹤0.01%	3805
2025 Q1	$11.3K	Buy	+1,506	New	+$12K	﹤0.01%	3782
2024 Q4	–	Sell	-57	Closed	-$396	–	4937
2024 Q3	$396	Hold	57	–	–	﹤0.01%	4594
2024 Q2	$279	Buy	57 +33	+138%	+$156	﹤0.01%	4607
2024 Q1	$139	Buy	24 +8	+50%	+$49	﹤0.01%	4634
2023 Q4	$105	Buy	+16	New	+$75	﹤0.01%	4519
2019 Q4	–	Sell	-188	Closed	-$2K	–	4125
2019 Q3	$2K	Buy	+188	New	+$3.4K	﹤0.01%	3876

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PNC Financial Services Group's ZVRA Position: Q2 2026 in Review

PNC Financial Services Group increased its Zevra Therapeutics (ZVRA) stake by 20% in Q2 2026, buying an estimated $623 and bringing the position to 338 shares worth $4.85K. The position accounts for ﹤0.01% of the portfolio, ranked #4402.

PNC Financial Services Group first reported a position in ZVRA in Q3 2019 and has held it in 11 quarters since. The position peaked at $12.5K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

PNC Financial Services Group held 338 shares of Zevra Therapeutics worth $4.85K as of Q2 2026.
PNC Financial Services Group bought 56 Zevra Therapeutics shares in Q2 2026, an estimated $623.
Zevra Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4402 holding.
PNC Financial Services Group first reported a position in Zevra Therapeutics in Q3 2019 and has held it in 11 quarters since.
PNC Financial Services Group's Zevra Therapeutics position peaked at $12.5K in Q3 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.